Search

Your search keyword '"Carlier, Nicolas"' showing total 107 results

Search Constraints

Start Over You searched for: Author "Carlier, Nicolas" Remove constraint Author: "Carlier, Nicolas"
107 results on '"Carlier, Nicolas"'

Search Results

2. The expanded French compassionate programme for elexacaftor–tezacaftor–ivacaftor use in people with cystic fibrosis without a F508del CFTR variant: a real-world study

3. Lack of association between classical HLA genes and asymptomatic SARS-CoV-2 infection

5. Characteristics and outcomes of COVID-19 patients admitted to hospital with and without respiratory symptoms

6. Immunomodulators for immunocompromised patients hospitalized for COVID-19: a meta-analysis of randomized controlled trials

7. Association of Country Income Level With the Characteristics and Outcomes of Critically Ill Patients Hospitalized With Acute Kidney Injury and COVID-19

8. Thrombotic and hemorrhagic complications of COVID-19 in adults hospitalized in high-income countries compared with those in adults hospitalized in low- and middle-income countries in an international registry

9. Sarilumab in adults hospitalised with moderate-to-severe COVID-19 pneumonia (CORIMUNO-SARI-1): An open-label randomised controlled trial

10. Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen : observational comparative study using routine care data

11. Fourteen-day survival among older adults with severe infection with severe acute respiratory syndrome coronavirus 2 treated with corticosteroid: a cohort study

12. Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial

13. The expanded French compassionate programme for elexacaftor–tezacaftor–ivacaftor use in people with cystic fibrosis without a F508del CFTRvariant: a real-world study

15. Reversal of cylindrical bronchial dilatations in a subset of adults with cystic fibrosis treated with elexacaftor/tezacaftor/ivacaftor

17. Platelet activation in critically ill COVID-19 patients

19. Association of Country Income Level With the Characteristics and Outcomes of Critically Ill Patients Hospitalized With Acute Kidney Injury and COVID-19

20. Thrombotic and hemorrhagic complications of COVID-19 in adults hospitalized in high-income countries compared with those in adults hospitalized in low- and middle-income countries in an international registry

22. Pre-exposure prophylaxis with tixagevimab and cilgavimab (Evusheld) for COVID-19 among 1112 severely immunocompromised patients

23. Normalisation of circulating neutrophil counts after 12 months of elexacaftor-tezacaftor-ivacaftor in patients with advanced cystic fibrosis

24. Rare predicted loss-of-function variants of type I IFN immunity genes are associated with life-threatening COVID-19

25. Efficacy of three COVID-19 vaccine doses in lung transplant recipients: a multicentre cohort study

26. Plasma Endocan as a Biomarker of Thrombotic Events in COVID-19 Patients

28. Impact on disease mortality of clinical, biological, and virological characteristics at hospital admission and overtime in COVID‐19 patients

29. Respiratory support in patients with severe COVID-19 in the International Severe Acute Respiratory and Emerging Infection (ISARIC) COVID-19 study: a prospective, multinational, observational study

30. ISARIC-COVID-19 dataset: A Prospective, Standardized, Global Dataset of Patients Hospitalized with COVID-19

31. Severe COVID-19 is associated with hyperactivation of the alternative complement pathway

32. The value of open-source clinical science in pandemic response: lessons from ISARIC

33. COVID-19 symptoms at hospital admission vary with age and sex

34. Oxidative Stress and Inflammatory Biomarkers for the Prediction of Severity and ICU Admission in Unselected Patients Hospitalized with COVID-19

35. Rapid Improvement after Starting Elexacaftor–Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis and Advanced Pulmonary Disease

37. Additional file 1 of Platelet activation in critically ill COVID-19 patients

38. COVID-19 symptoms at hospital admission vary with age and sex: results from the ISARIC prospective multinational observational study

39. Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia

40. Additional file 2 of Platelet activation in critically ill COVID-19 patients

41. Plasma concentration and safety of lopinavir/ritonavir in patients with Covid-19: a retrospective cohort study

42. No evidence of clinical efficacy of hydroxychloroquine in patients hospitalized for COVID-19 infection with oxygen requirement: results of a study using routinely collected data to emulate a target trial

43. Dysregulated primary hemostasis in critically ill COVID-19 patients

44. Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients

46. Impaired type I interferon activity and exacerbated inflammatory responses in severe Covid-19 patients

47. No evidence of clinical efficacy of hydroxychloroquine in patients hospitalised for COVID-19 infection and requiring oxygen: results of a study using routinely collected data to emulate a target trial

49. Comparaison de l’efficience de cinq souches de Rhizobium sur 18 génotypes de pois

Catalog

Books, media, physical & digital resources